Fibroblast growth factor 7 (FGF7)

Fibroblast growth factor 7 (FGF7), also known as keratinocyte growth factor (KGF), is a secreted protein primarily produced by mesenchymal cells and acts specifically on epithelial cells through the FGFR2b receptor[1][2][3]. It is a potent epithelial cell-specific mitogen and plays critical roles in embryonic organ development, reepithelialization after injury, cell proliferation, and tissue repair. FGF7 signaling is crucial in regulating epithelial homeostasis, wound healing, and organogenesis. Dysregulation or abnormal activation of FGF7 is implicated in pathological conditions including cancer (promotes cell proliferation, invasion, and resistance to chemotherapy), fibrosis, cyst formation, metabolic disorders, and chronic inflammatory diseases. Palifermin (recombinant FGF7) is an approved therapeutic protein to mitigate oral mucositis in cancer patients, illustrating FGF7's therapeutic validity and clinical relevance[1][2][4].

Other names

Keratinocyte growth factorKGFFGF-7

Palifermin: Binds and activates FGFR2b (fibroblast growth factor receptor 2b) on epithelial cells, stimulating proliferation, migration, and differentiation, thus promoting mucosal healing and reducing tissue injury. General FGF7 pathway inhibitors (under development): block its downstream effects on epithelial proliferation and survival. Targeting FGF7/FGFR pathways may also be explored for anti-fibrotic or anti-tumorigenic actions.